课题基金 / 基金详情

IDO Inhibitors for Combinatorial Cancer Therapy

IDO Inhibitors for Combinatorial Cancer Therapy
用于组合癌症治疗的 IDO 抑制剂
批准号:
6925262
负责人:
GEORGE C PRENDERGAST
金额:
$29.37万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-04-01 至 2008-03-31

项目摘要

项目成果

GEORGE C PRENDERGAST的其他基金

相似基金

相关文献

中文摘要
翻译
简介(申请人提供):背景。消除系统性癌症的策略亟需改进。考虑到免疫逃避在癌症中普遍存在,免疫干预可能是有用的。癌症用来逃避免疫的一种机制是通过激活免疫抑制酶IDO(吲哚胺2,3-双加氧酶)来调节的,这种酶限制了细胞毒性T细胞的激活。我们通过Bin 1的基因控制鉴定了IDO,Bin 1是一种肿瘤抑制因子,通常在乳腺癌和其他癌症中减弱。小鼠基因敲除研究将Bin 1的缺失与恶性能力的增加联系在一起,部分是通过IDO介导的免疫逃避。如果Bin 1或其他抑癌基因中的病变通过升高IDO来促进免疫逃逸,那么IDO活性的小分子抑制剂将被预测为促进肿瘤细胞的免疫排斥。指导假设和具体目标:初步研究表明,在乳腺癌转基因小鼠模型(MMTVneu小鼠)中,生物活性IDO抑制剂与细胞毒性化疗药物的结合会引发大量肿瘤细胞死亡和消退,而单一药物是无效的。IDO抑制剂在体外没有细胞毒性,因此它们的抗肿瘤活性不会被传统的体外药物筛选所揭示。在目标1中,我们将改变IDO抑制剂的剂量和时间安排,以优化疗效。在目标2和目标3中,我们将合成并测定已鉴定的四个系列IDO抑制剂的化合物的酶抑制活性。最后,在目标4和目标5中,将审查先导化合物的药理和功效。我们的长期目标是为这一新治疗策略的临床开发奠定基础。创新和意义:提供了几项创新。最普遍的创新是一个未知的概念,即通过结合免疫治疗和细胞毒化疗,癌症治疗可能会得到加强。IDO的生物化学很发达,但其在癌症中的病理生理作用几乎没有被探索:IDO的小分子抑制剂为癌症治疗提供了一种新的方式,它们提供了一种化学遗传学工具来确定IDO对肿瘤免疫和生存的意义。IDO作为抗癌药物靶点具有诱人的特点,包括它的药理可控性、它缺乏基因组亲缘关系以及它的药效学测量简便。这项应用提供了一个独特的机会,以获得癌症病理生理学和治疗的创新视角。
英文摘要
DESCRIPTION (provided by applicant): Background. There is a great need for improved strategies to eliminate systemic cancer. Immune interventions may be useful given that immune evasion occurs universally in cancer. One mechanism cancers use to evade immunity is mediated by activation of the immunosuppressive enzyme, IDO (indoleamine 2, 3-dioxygenase), which limits activation of cytotoxic T cells. We identified IDO through its genetic control by Bin 1, a tumor suppressor commonly attenuated in breast cancers and other cancers. Mouse knockout studies link Bin 1 loss to increased malignant capacity, in part via IDO-mediated immune evasion. If lesions in Bin 1 or other tumor suppressors promote immune evasion by elevating IDO, then small molecule inhibitors of IDO activity would be predicted to promote immune rejection of tumor cells. Guiding Hypothesis and Specific Aims: Preliminary studies show that the combination of a bioactive IDO inhibitor with a cytotoxic chemotherapeutic drug triggers massive tumor cell deaths and regression in a transgenic mouse model of breast cancer (MMTVneu mice), where single agents are ineffective. IDO inhibitors are not cytotoxic in vitro, so their antitumor activity would not be revealed by traditional in vitro drug screens. In Aim 1, we will vary dosing and scheduling of an IDO inhibitor to optimize efficacy. In Aims 2 and 3, we will synthesize and assay the enzyme inhibitory activity of compounds in four series of IDO inhibitors that have been identified. Lastly, in Aims 4 and 5, the pharmacology and efficacy of lead compounds will be examined. Our long-term goal is to build a foundation for clinical development of this new therapeutic strategy. Innovation and Significance: Several innovations are offered. The most general innovation is the unexplored concept that cancer treatment might be enhanced by combining immunotherapy and cytotoxic chemotherapy. The biochemistry of IDO is well developed, but its pathophysiological role in cancer is virtually unexplored: Small molecule inhibitors of IDO provide a new modality for cancer therapy, and they offer a tool for chemical genetics to establish the significance of IDO to tumor immunity and survival. IDO has attractive features as a cancer drug target, including its pharmacological tractability, its lack of genomic relatives, and its facile pharmacodynamic measurement. This application offers a unique opportunity to gain an innovative perspective on cancer pathophysiology and treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis
IDO2 Targeting in Pancreatic Cancer
OPPC targeting to improve pancreatic cancer treatment
海外基金